The makers of Mounjaro and Ozempic are facing a new lawsuit accusing the manufacturers of not revealing to patients a stomach paralysis side effect that in part helps make the drugs effective when it comes to weight loss.

The lawsuit was filed by 44-year-old Louisiana woman, Jaclyn Bjorklund. Attorneys representing Bjorklund detail that she suffered severe injuries after she was prescribed the drugs and that her injuries were brought on by the injectable medications.

Mounjaro is one of several drugs that was originally prescribed to treat conditions caused by insulin resistance. While initially marketed as a diabetes management drug, the effectiveness of Mounjaro and similar diabetes drugs in helping users lose weight has spiked demand for them over the past year.

Monjarno, along with other brands Wegovy and Ozempic, has become the drug of choice for individuals of all sizes looking to shed stubborn weight. In recent months, individuals who struggle with weight loss have been prescribed the injectables as a means to manage their weight.

Despite the drug's popularity for weight loss, this new lawsuit sheds light on the drugs’ negative side effects which are less talked about. The lawsuit claims that the drugs can cause a condition called gastroparesis, which is essentially a paralysis of the stomach, and that the drug makers failed to accurately warn individuals about this medical complication. Gastroparesis is a condition in which gastric emptying is delayed. Users suffering from the condition can experience a slowing or stoppage of food moving from the stomach to the small intestine.

In announcing the lawsuit, Paul Pennock and Jonathan Sedgh, the attorneys representing Bjorklund, explained, "It is our opinion that these drugs are causing these problems. We think that the evidence is sufficient for us to be able to prove it or we would not have filed the case, and we intend to file many more in the coming days and weeks."

Pennock and Sedgh shared how drugs adversely impacted Bjorklund and that she began experiencing side effects that landed her in the emergency room “multiple times.” At one point, Bjorklund even began throwing up so violently that she lost teeth. Bjorklund’s attorneys add that they are investigating at least 400 other cases across 45 states.

Bjorklund’s lawsuit describes that she “was caused to suffer from severe gastrointestinal events, and as a result sustained severe and permanent personal injuries, pain, suffering, and emotional distress, and incurred medical expenses.”

Allegedly, because the drug makers Novo Nordisk and Eli Lilly failed to adequately warn consumers about these potential side effects, Bjorklund and others like her were made to suffer unnecessarily.

Mounjaro, which is the brand name of Tirzepatide, is known as a GIP and GLP-1 receptor agonist. Ozempic and Wegovy are the name brands of Semaglutide and are known as GLP-1 receptor agonists.

The lawsuit explains that the drug makers “knew of the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis.” But their “failure to disclose information that they possessed regarding the association between the use of GLP-1 receptor agonists and the risk of developing severe gastrointestinal issues, including gastroparesis and gastroenteritis, rendered the warnings for this medication inadequate.”

Eli Lilly and Co. has responded to the lawsuit, saying, "Patient safety is Lilly's top priority, and we actively engage in monitoring and reporting safety information for all our medicines."

Novo Nordisk also shared a statement that explained that GI events were "well-known side effects of the GLP-1 class" and that "For semaglutide, the majority of GI side effects are mild to moderate in severity and of short duration. GLP-1's are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea and vomiting are listed as side effects."

Bjorklund is seeking compensatory and punitive damages for past and future healthcare costs, medical monitoring costs, and pain and suffering. She is also seeking attorney's fees and court costs.